HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Kyverna Therapeutics, Inc.

Contributing Author

Recent Articles by Kyverna Therapeutics, Inc.

Mar-26
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results KYTX GlobeNewswire
Mar-05
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 KYTX -5.41% GlobeNewswire
Mar-03
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences KYTX -5.76% GlobeNewswire
Feb-24
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors KYTX GlobeNewswire
Feb-03
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer KYTX GlobeNewswire
Jan-12
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference KYTX GlobeNewswire
Jan-05
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference KYTX -7.30% GlobeNewswire
Dec-17
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock KYTX -32.52% GlobeNewswire
Dec-15
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock KYTX +23.23% KYTX -5.36% GlobeNewswire
Dec-15
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome KYTX +23.23% GlobeNewswire
Dec-14
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome KYTX GlobeNewswire
Nov-12
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results KYTX -11.60% KYTX GlobeNewswire
Nov-10
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference KYTX GlobeNewswire
Nov-03
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance KYTX GlobeNewswire
Oct-29
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 KYTX -5.78% GlobeNewswire
Oct-25
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 KYTX GlobeNewswire
Oct-22
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis KYTX -6.58% GlobeNewswire
Sep-24
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS KYTX GlobeNewswire
Sep-15
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 KYTX GlobeNewswire
Aug-28
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event KYTX GlobeNewswire
Aug-25
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September KYTX GlobeNewswire
Aug-12
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results KYTX +14.90% KYTX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)